Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with news that STAT+, our exclusive source for trusted and authoritative coverage of the life sciences, is on sale this week. Claim your exclusive offer now and save 40% with code STAT40.
Acadia’s schizophrenia drug fails in pivotal study
Acadia Pharmaceuticals’ treatment for schizophrenia missed its primary goal in a pivotal study, the company said yesterday, pointing to an unexpectedly strong placebo effect.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect